CoCites: A citation-based method for searching scientific literature

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?

Masayuki Takeda, Kazuhiko Nakagawa. Int J Mol Sci 2019
Times Cited: 65

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, Shunichi Negoro, Isamu Okamoto, Junji Tsurutani, Takashi Seto, Miyako Satouchi, Hirohito Tada, Tomonori Hirashima, Kazuhiro Asami, Nobuyuki Katakami, Minoru Takada, Hiroshige Yoshioka, Kazuhiko Shibata, Shinzoh Kudoh, Eiji Shimizu, Hiroshi Saito, Shinichi Toyooka, Kazuhiko Nakagawa, Masahiro Fukuoka. Lancet Oncol 2010
Times Cited: 3099

List of shared articles

Times cited

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models.
Ilaria Marrocco, Donatella Romaniello, Itay Vaknin, Diana Drago-Garcia, Roni Oren, Mary Luz Uribe, Nishanth Belugali Nataraj, Soma Ghosh, Raya Eilam, Tomer-Meir Salame,[...]. EMBO Mol Med 2021

Efficacy and Safety of First-Generation EGFR-TKIs Combined with Chemotherapy for Treatment-Naïve Advanced Non-Small-Cell Lung Cancer Patients Harboring Sensitive EGFR Mutations: A Single-Center, Open-Label, Single-Arm, Phase II Clinical Trial.
Jinghui Lin, Meifang Li, Shijie Chen, Lihong Weng, Zhiyong He. J Inflamm Res 2021

Leveraging Bulk and Single-Cell RNA Sequencing Data of NSCLC Tumor Microenvironment and Therapeutic Potential of NLOC-15A, A Novel Multi-Target Small Molecule.
Bashir Lawal, Alexander T H Wu, Hsu-Shan Huang. Front Immunol 2022

An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece.
Giannis Mountzios, Sofia Lampaki, Georgia-Angeliki Koliou, Athanassios Vozikis, Ioannis Kontogiorgos, Panagiotis Papantoniou, Margarita-Ioanna Koufaki, Eleni Res, Anastasios Boutis, Athina Christopoulou,[...]. Lung Cancer (Auckl) 2021

Front-line Therapy in Advanced Non-Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: A Network Meta-analysis.
Xu-Yuan Li, Jia-Zhou Lin, Shu-Han Yu. Clin Ther 2020

Meta-Analysis of Aidi Injection and First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy in Treating Advanced Non-Small Cell Lung Cancer.
Na Xiao, Hailang He, Jing Wang, Li Zhang, Brandon Chow, Fanchao Feng, Yong Xu, Jingyi Huang, Xianmei Zhou, Rui Dong. J Evid Based Integr Med 2021

A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The 'LUNGFUL' Study.
Giannis Mountzios, Anna Koumarianou, Alexandros Bokas, Dimitrios Mavroudis, Epaminondas Samantas, Evangelos Georgios Fergadis, Helena Linardou, Panagiotis Katsaounis, Elias Athanasiadis, Michalis V Karamouzis,[...]. Cancers (Basel) 2021

Efficacy and Safety of EGFR Inhibitors in the Treatment of EGFRPositive NSCLC Patients: A Meta-Analysis.
Amit Dang, Sumit Dang, B N Vallish. Rev Recent Clin Trials 2021

Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Yosuke Miyashita, Ryo Ko, Naoko Shimada, Yoichiro Mitsuishi, Keita Miura, Naohisa Matsumoto, Tetsuhiko Asao, Takehito Shukuya, Rina Shibayama, Ryo Koyama,[...]. Thorac Cancer 2021

Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer.
Jacopo Giuliani, Andrea Bonetti. Cancer Drug Resist 2021

Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective.
Umberto Malapelle, Sara Pilotto, Francesco Passiglia, Francesco Pepe, Pasquale Pisapia, Luisella Righi, Angela Listì, Paolo Bironzo, Lorenzo Belluomini, Fabrizio Tabbò,[...]. Crit Rev Oncol Hematol 2021

Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial.
Xi Li, Li Zhang, Da Jiang, Yan Wang, Aimin Zang, Cuimin Ding, Min Zhao, Wuyun Su, Yan Zhang, Diansheng Zhong,[...]. Clin Cancer Res 2020

EGFR signaling pathway as therapeutic target in human cancers.
Elena Levantini, Giorgia Maroni, Marzia Del Re, Daniel G Tenen. Semin Cancer Biol 2022